<DOC>
	<DOCNO>NCT00601692</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Irinotecan may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Irinotecan docetaxel may also make tumor cell sensitive radiation therapy . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel give together irinotecan radiation therapy without cisplatin treat patient locally advanced esophageal cancer .</brief_summary>
	<brief_title>Irinotecan , Radiation Therapy , Docetaxel With Without Cisplatin Treating Patients With Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine dose limit toxicity recommend phase II dose docetaxel give escalate dos weekly irinotecan hydrochloride concurrent radiotherapy patient locally advanced esophageal cancer . - To determine dose limit toxicity cisplatin , recommend phase II dose docetaxel establish , give weekly docetaxel , irinotecan hydrochloride , concurrent radiotherapy patient locally advanced esophageal cancer . Secondary - To evaluate clinical pathological complete response rate patient locally advanced esophageal cancer treat induction chemotherapy comprise docetaxel irinotecan hydrochloride without cisplatin follow concurrent docetaxel irinotecan hydrochloride without cisplatin plus radiotherapy . OUTLINE : Patients receive one follow regimen . Regimen 2 patient recruit recommended phase II dose determine patient recruit ( receive regimen 1 ) . - Regimen 1 : - Induction chemotherapy ( week 1-6 ) : Patients receive docetaxel IV 15 minute irinotecan hydrochloride IV 30 minute day 1 8 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . - Chemoradiotherapy ( week 8-13 ) : Beginning week 8 , patient receive docetaxel IV 15 minute irinotecan hydrochloride IV 30 minute day 1 ( week 8 ) 8 ( week 9 ) . Patients also undergo radiotherapy daily , 5 day week , week 8-10 . Treatment chemoradiotherapy repeat every 3 week 2 course absence disease progression unacceptable toxicity . - Regimen 2 : - Induction chemotherapy ( week 1-6 ) : Patients receive docetaxel IV irinotecan hydrochloride regimen 1 induction chemotherapy . They also receive cisplatin IV 20-30 minute day 1 8 . Treatment irinotecan hydrochloride , docetaxel , cisplatin repeat every 3 week 2 course absence disease progression unacceptable toxicity . - Chemoradiotherapy ( week 8-13 ) : Patients receive docetaxel IV , irinotecan hydrochloride IV , undergo radiotherapy regimen 1 chemoradiotherapy . Patients also receive cisplatin IV 20-30 minute day 1 ( week 8 ) 8 ( week 9 ) . Treatment irinotecan hydrochloride , docetaxel , cisplatin , radiotherapy repeat every 3 week 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm squamous cell carcinoma , adenocarcinoma , poorly differentiate carcinoma , carcinoma otherwise specify , esophagus gastroesophageal ( GE ) junction Disease clinically limit esophagus GE junction ( T1 , N1 , M0 , T24 , N , M0 ) M1a metastatic disease lymph node allow Includes celiac lymph node patient distal third esophageal primary lesion gastroesophageal junction primary supraclavicular lymph node patient proximal third esophageal lesion Disease must able contained radiotherapy field Previously untreated patient primary tumor cervical thoracic esophagus , include GE junction , eligible study At least 50 % tumor must involve distal esophagus tumor GE junction Exclusion criterion : Positive malignant cytology pleura , pericardium , peritoneum Metastatic disease distant organ ( e.g . liver ) nonregional lymph node Biopsy proven tumor invasion tracheobronchial tree tracheoesophageal fistula PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status ( PS ) 70100 % OR ECOG PS 02 ANC ≥ 1,500 cells/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 mg/dL Creatinine ≤ 1.5 mg/dL Total serum bilirubin ≤ 1.0 mg/dL AST ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Men woman child bear potential must use effective contraception treatment reasonable period thereafter Negative pregnancy test Exclusion criterion : History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 Preexisting peripheral neuropathy &gt; grade 1 Severe comorbid condition include , limited , follow : NYHA class IIIIV cardiac disease Myocardial infarction within past 6 month Severe uncontrolled diabetes Hypercalcemia Uncontrolled hypertension Cerebral vascular disease Uncontrolled infection Pregnant lactate woman History prior malignancy diagnose and/or treat within past three year , except basal cell squamous cell carcinoma skin , carcinoma situ cervix , superficial transitional cell carcinoma bladder Known Gilbert disease History seizure disorder concurrent phenytoin , phenobarbital , antiepileptic medication Any concurrent medical psychiatric condition disease , investigator 's judgment , would make patient inappropriate entry study Patients fully comprehend therapeutic implication protocol comply requirement PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy ( RT ) esophageal cancer No prior mantle RT , chest RT , pelvic RT , hemibody RT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>